Loading clinical trials...
Loading clinical trials...
A Single Cross-Over, Open-Label Study of the Relative Bioavailability of Probuphine Versus Buprenorphine Sublingual Tablets at Steady State in Patients With Opioid Dependence
Conditions
Interventions
Probuphine (buprenorphine implant)
Sublingual Buprenorphine
Locations
1
United States
Segal Institute For Clinical Research
Fort Lauderdale, Florida, United States
Start Date
September 1, 2008
Primary Completion Date
December 1, 2008
Completion Date
December 1, 2008
Last Updated
December 31, 2018
NCT05463367
NCT03345173
NCT04454411
NCT03842137
NCT06442306
NCT05995873
Lead Sponsor
Titan Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions